Tyrosine kinase inhibitor activity on BCR-ABL1 mutations in chronic myeloid leukemia
Tyrosine kinase inhibitor activity on BCR-ABL1 mutations in chronic myeloid leukemia
Activity of imatinib mesylate and the second generation tyrosine kinase inhibitors nilotinib and dasatinib against a selection of BCR-ABL1 mutants found in patients with CML. All concentrations are shown in nanomoles per milliliter and represent IC50 values.